DOCSLIB.ORG

Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Use this chart to code histology. The tree is arranged Chart Instructions: Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Ependymal Embryonal Pineal Choro id plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Pineoblastoma Ependymoma, Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) Oligodendroglioma (9390) (9505 Olfactory neurocytoma Ganglioglioma, malignant (()9521) anaplastic (()9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Supratentorial primitive Atypical EdEpendymo bltblastoma MdllMedulloep ithliithelioma Medulloblastoma neuroectodermal tumor tetratoid/rhabdoid (9392) (9501) (9470) (PNET) (9473) tumor (9508) Teratoid Demoplastic (9471) Neuroblastoma (9500) medulloepthelioma Large cell (9474) Ganglioneuroblastoma (9502) Medullomyoblastoma (9490) (9472) Mixed glioma Glial tumors of (9382) Astrocytic un certain tumors origin Astroblastoma (9430) Gliomatosis cerebri (9381) Pilocytic Pleomorphic Astrocytoma, Polar spongioblastoma astrocytoma xanthoastrocytoma NOS (9400) (9423) (9421) (9424) Chart 1 Anaplastic astrocytoma Glioblastoma, NOS Pg 72 (9401) and Glioblastoma Fibrillary astrocytoma multiforme (9440) (9420) Gemistocytic Giant cell glioblastoma astrocytoma (9411) (9441) Key:The ovals( )represent Protoplasmic Gliosarcoma (9442) group terms. astromytoma (9410) Chart 2 –Non‐neuroepithelial Malignant Brain and Central Nervous System Tumors Non‐ Neuroepithelial Peripheral Germ Cell Meningioma, Nerve Tumors malignant Perineurioma, Germinoma malignant (()9064) (9571) Use this chart to code histology. The tree is arranged Chart Instructions: Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Ependymal Embryonal Pineal Choro id plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Pineoblastoma Ependymoma, Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) Oligodendroglioma (9390) (9505 Olfactory neurocytoma Ganglioglioma, malignant (()9521) anaplastic (()9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Supratentorial primitive Atypical EdEpendymo bltblastoma MdllMedulloep ithliithelioma Medulloblastoma neuroectodermal tumor tetratoid/rhabdoid (9392) (9501) (9470) (PNET) (9473) tumor (9508) Teratoid Demoplastic (9471) Neuroblastoma (9500) medulloepthelioma Large cell (9474) Ganglioneuroblastoma (9502) Medullomyoblastoma (9490) (9472) Mixed glioma Glial tumors of (9382) Astrocytic un certain tumors origin Astroblastoma (9430) Gliomatosis cerebri (9381) Pilocytic Pleomorphic Astrocytoma, Polar spongioblastoma astrocytoma xanthoastrocytoma NOS (9400) (9423) (9421) (9424) Anaplastic astrocytoma Glioblastoma, NOS (9401) and Glioblastoma Fibrillary astrocytoma multiforme (9440) (9420) Gemistocytic Giant cell glioblastoma astrocytoma (9411) (9441) Key:The ovals( )represent Protoplasmic Gliosarcoma (9442) group terms. astromytoma (9410) Use this chart to code histology. The tree is arranged Chart Instructions: Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Ependymal Embryonal Pineal Choro id plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Pineoblastoma Ependymoma, Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) Oligodendroglioma (9390) (9505 Olfactory neurocytoma Ganglioglioma, malignant (()9521) anaplastic (()9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Supratentorial primitive Atypical EdEpendymo bltblastoma MdllMedulloep ithliithelioma Medulloblastoma neuroectodermal tumor tetratoid/rhabdoid (9392) (9501) (9470) (PNET) (9473) tumor (9508) Rule M7: Teratoid Demoplastic (9471) Neuroblastoma (9500) One primary medulloepthelioma Large cell (9474) Ganglioneuroblastoma (9502) Medullomyoblastoma (9490) (9472) Mixed glioma Glial tumors of (9382) Astrocytic un certain tumors origin Tumor 1: Astroblastoma (9430) Gliomatosis cerebri (9381) Pilocytic Pleomorphic Astrocytoma, Astrocytoma (NOS) Polar spongioblastoma astrocytoma xanthoastrocytoma NOS (9400) (9423) (9421) (9424) Tumor 2: Anaplastic astrocytoma Glioblastoma, NOS (9401) and Glioblastoma Anaplastic Fibrillary astrocytoma multiforme (9440) (9420) astrocytoma Gemistocytic Giant cell glioblastoma astrocytoma (9411) (9441) Key:The ovals( )represent Protoplasmic Gliosarcoma (9442) group terms. astromytoma (9410) Use this chart to code histology. The tree is arranged Chart Instructions: Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Ependymal Embryonal Pineal Choro id plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Pineoblastoma Ependymoma, Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) Oligodendroglioma (9390) (9505 Olfactory neurocytoma Ganglioglioma, malignant (()9521) anaplastic (()9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Supratentorial primitive Atypical EdEpendymo bltblastoma MdllMedulloep ithliithelioma Medulloblastoma neuroectodermal tumor tetratoid/rhabdoid (9392) (9501) (9470) (PNET) (9473) tumor (9508) Rule M8: Teratoid Demoplastic (9471) Neuroblastoma (9500) Two primaries medulloepthelioma Large cell (9474) Ganglioneuroblastoma (9502) Medullomyoblastoma (9490) (9472) Mixed glioma Glial tumors of (9382) Astrocytic un certain tumors origin Tumor 2: Astroblastoma Astroblastoma (9430) Gliomatosis cerebri (9381) Pilocytic Pleomorphic Astrocytoma, Polar spongioblastoma astrocytoma xanthoastrocytoma NOS (9400) (9423) (9421) (9424) Anaplastic astrocytoma Glioblastoma, NOS (9401) and Glioblastoma Tumor 1: Fibrillary astrocytoma multiforme (9440) (9420) Astrocytoma (NOS) Gemistocytic Giant cell glioblastoma astrocytoma (9411) (9441) Key:The ovals( )represent Protoplasmic Gliosarcoma (9442) group terms. astromytoma (9410).
Load more

Recommended publications
  • Risk Factors for Gliomas and Meningiomas in Males in Los Angeles County1
    [CANCER RESEARCH 49, 6137-6143. November 1, 1989] Risk Factors for Gliomas and Meningiomas in Males in Los Angeles County1 Susan Preston-Martin,2 Wendy Mack, and Brian E. Henderson Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033 ABSTRACT views with proxy respondents, we were unable to include a large proportion of otherwise eligible cases because they were deceased or Detailed job histories and information about other suspected risk were too ill or impaired to participate in an interview. The Los Angeles factors were obtained during interviews with 272 men aged 25-69 with a County Cancer Surveillance Program identified the cases (26). All primary brain tumor first diagnosed during 1980-1984 and with 272 diagnoses had been microscopically confirmed. individually matched neighbor controls. Separate analyses were con A total of 478 patients were identified. The hospital and attending ducted for the 202 glioma pairs and the 70 meningioma pairs. Meningi- physician granted us permission to contact 396 (83%) patients. We oma, but not glioma, was related to having a serious head injury 20 or were unable to locate 22 patients, 38 chose not to participate, and 60 more years before diagnosis (odds ratio (OR) = 2.3; 95% confidence were aphasie or too ill to complete the interview. We interviewed 277 interval (CI) = 1.1-5.4), and a clear dose-response effect was observed patients (74% of the 374 patients contacted about the study or 58% of relating meningioma risk to number of serious head injuries (/' for trend the initial 478 patients).
    [Show full text]
  • Central Nervous System Cancers Panel Members Can Be Found on Page 1151
    1114 NCCN David Tran, MD, PhD; Nam Tran, MD, PhD; Frank D. Vrionis, MD, MPH, PhD; Patrick Y. Wen, MD; Central Nervous Nicole McMillian, MS; and Maria Ho, PhD System Cancers Overview In 2013, an estimated 23,130 people in the United Clinical Practice Guidelines in Oncology States will be diagnosed with primary malignant brain Louis Burt Nabors, MD; Mario Ammirati, MD, MBA; and other central nervous system (CNS) neoplasms.1 Philip J. Bierman, MD; Henry Brem, MD; Nicholas Butowski, MD; These tumors will be responsible for approximately Marc C. Chamberlain, MD; Lisa M. DeAngelis, MD; 14,080 deaths. The incidence of primary brain tumors Robert A. Fenstermaker, MD; Allan Friedman, MD; Mark R. Gilbert, MD; Deneen Hesser, MSHSA, RN, OCN; has been increasing over the past 30 years, especially in Matthias Holdhoff, MD, PhD; Larry Junck, MD; elderly persons.2 Metastatic disease to the CNS occurs Ronald Lawson, MD; Jay S. Loeffler, MD; Moshe H. Maor, MD; much more frequently, with an estimated incidence ap- Paul L. Moots, MD; Tara Morrison, MD; proximately 10 times that of primary brain tumors. An Maciej M. Mrugala, MD, PhD, MPH; Herbert B. Newton, MD; Jana Portnow, MD; Jeffrey J. Raizer, MD; Lawrence Recht, MD; estimated 20% to 40% of patients with systemic cancer Dennis C. Shrieve, MD, PhD; Allen K. Sills Jr, MD; will develop brain metastases.3 Abstract Please Note Primary and metastatic tumors of the central nervous system are The NCCN Clinical Practice Guidelines in Oncology a heterogeneous group of neoplasms with varied outcomes and (NCCN Guidelines®) are a statement of consensus of the management strategies.
    [Show full text]
  • Intraventricular Neuroepithelial Tumors: Surgical Outcome, Technical Considerations and Review of Literature A
    Aftahy et al. BMC Cancer (2020) 20:1060 https://doi.org/10.1186/s12885-020-07570-1 RESEARCH ARTICLE Open Access Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature A. Kaywan Aftahy1* , Melanie Barz1, Philipp Krauss1, Friederike Liesche2, Benedikt Wiestler3, Stephanie E. Combs4,5,6, Christoph Straube4, Bernhard Meyer1 and Jens Gempt1 Abstract Background: Intraventricular neuroepithelial tumors (IVT) are rare lesions and comprise different pathological entities such as ependymomas, subependymomas and central neurocytomas. The treatment of choice is neurosurgical resection, which can be challenging due to their intraventricular location. Different surgical approaches to the ventricles are described. Here we report a large series of IVTs, its postoperative outcome at a single tertiary center and discuss suitable surgical approaches. Methods: We performed a retrospective chart review at a single tertiary neurosurgical center between 03/2009–05/ 2019. We included patients that underwent resection of an IVT emphasizing on surgical approach, extent of resection, clinical outcome and postoperative complications. Results: Forty five IVTs were resected from 03/2009 to 05/2019, 13 ependymomas, 21 subependymomas, 10 central neurocytomas and one glioependymal cyst. Median age was 52,5 years with 55.6% (25) male and 44.4% (20) female patients. Gross total resection was achieved in 93.3% (42/45). 84.6% (11/13) of ependymomas, 100% (12/21) of subependymomas, 90% (9/10) of central neurocytomas and one glioependymal cyst were completely removed. Postoperative rate of new neurological deficits was 26.6% (12/45). Postoperative new permanent cranial nerve deficits occurred in one case with 4th ventricle subependymoma and one in 4th ventricle ependymoma.
    [Show full text]
  • Malignant Glioma Arising at the Site of an Excised Cerebellar Hemangioblastoma After Irradiation in a Von Hippel-Lindau Disease Patient
    DOI 10.3349/ymj.2009.50.4.576 Case Report pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 50(4): 576-581, 2009 Malignant Glioma Arising at the Site of an Excised Cerebellar Hemangioblastoma after Irradiation in a von Hippel-Lindau Disease Patient Na-Hye Myong1 and Bong-Jin Park2 1Department of Pathology, Dankook University College of Medicine, Cheonan; 2Department of Neurosurgery, Kyunghee University Hospital, Seoul, Korea. We describe herein a malignant glioma arising at the site of the resected hemangioblastoma after irradiation in a patient with von Hippel-Lindau disease (VHL). The patient was a 25 year-old male with multiple heman- gioblastomas at the cerebellum and spinal cord, multiple pancreatic cysts and a renal cell carcinoma; he was diagnosed as having VHL disease. The largest hemangioblastoma at the right cerebellar hemisphere was completely removed, and he received high-dose irradiation postoperatively. The tumor recurred at the same site 7 years later, which was a malignant glioma with no evidence of hemangioblastoma. The malignant glioma showed molecular genetic profiles of radiation-induced tumors because of its diffuse p53 immunostaining and the loss of p16 immunoreactivity. The genetic study to find the loss of heterozygosity (LOH) of VHL gene revealed that only the cerebellar hemangioblastoma showed allelic losses for the gene. To the best of our knowledge, this report is the first to show a malignant glioma that developed in a patient with VHL disease after radiation therapy at the site of an excised hemangioblastoma. This report also suggests that radiation therapy should be performed very carefully in VHL patients with hemangioblastomas.
    [Show full text]
  • Original Article Outcome of Supratentorial Intraaxial Extra Ventricular Primary Pediatric Brain Tumors
    Original Article Outcome of supratentorial intraaxial extra ventricular primary pediatric brain tumors: A prospective study Mohana Rao Patibandla, Suchanda Bhattacharjee1, Megha S. Uppin2, Aniruddh Kumar Purohit1 Department of Neurosurgery, Krishna Institute of Medical Sciences Secunderabad, Departments of 1Neurosurgery and 2Pathology, Nizam’s Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India Address for correspondence: Dr. Mohana Rao Patibandla, Department of Neurosurgery, University of Colorado Denver, 13123, E 16th Ave, Aurora, CO 80045, USA. Email: [email protected] ABSTRACT Introduction: Tumors of the central nervous system (CNS) are the second most frequent malignancy of childhood and the most common solid tumor in this age group. CNS tumors represent approximately 17% of all malignancies in the pediatric age range, including adolescents. Glial neoplasms in children account for up to 60% of supratentorial intraaxial tumors. Their histological distribution and prognostic features differ from that of adults. Aims and Objectives: To study clinical and pathological characteristics, and to analyze the outcome using the Engel’s classification for seizures, Karnofsky’s score during the available follow‑up period of minimum 1 year following the surgical and adjuvant therapy of supratentorial intraaxial extraventricular primary pediatric (SIEPP) brain tumors in children equal or less than 18 years. Materials and Methods: The study design is a prospective study done in NIMS from October 2008 to January 2012. All the patients less than 18 years of age operated for SIEPP brain tumors proven histopathologically were included in the study. All the patients with recurrent or residual primary tumors or secondaries were excluded from the study. Post operative CT or magnetic resonance imaging (MRI) is done following surgery.
    [Show full text]
  • Paraganglioma (PGL) Tumors in Patients with Succinate Dehydrogenase-Related PCC–PGL Syndromes: a Clinicopathological and Molecular Analysis
    T G Papathomas and others Non-PCC/PGL tumors in the SDH 170:1 1–12 Clinical Study deficiency Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC–PGL syndromes: a clinicopathological and molecular analysis Thomas G Papathomas1, Jose Gaal1, Eleonora P M Corssmit2, Lindsey Oudijk1, Esther Korpershoek1, Ketil Heimdal3, Jean-Pierre Bayley4, Hans Morreau5, Marieke van Dooren6, Konstantinos Papaspyrou7, Thomas Schreiner8, Torsten Hansen9, Per Arne Andresen10, David F Restuccia1, Ingrid van Kessel6, Geert J L H van Leenders1, Johan M Kros1, Leendert H J Looijenga1, Leo J Hofland11, Wolf Mann7, Francien H van Nederveen12, Ozgur Mete13,14, Sylvia L Asa13,14, Ronald R de Krijger1,15 and Winand N M Dinjens1 1Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands, 2Department of Endocrinology, Leiden University Medical Center, Leiden,The Netherlands, 3Section for Clinical Genetics, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway, 4Department of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands, 5Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, 6Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, 7Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany, 8Section for Specialized Endocrinology,
    [Show full text]
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • Seizure Prognosis of Patients with Low-Grade Tumors
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Seizure 21 (2012) 540–545 Contents lists available at SciVerse ScienceDirect Seizure jou rnal homepage: www.elsevier.com/locate/yseiz Seizure prognosis of patients with low-grade tumors a b,c c,d c,e Cynthia A. Kahlenberg , Camilo E. Fadul , David W. Roberts , Vijay M. Thadani , c,e a,f c,e, Krzysztof A. Bujarski , Rod C. Scott , Barbara C. Jobst * a Dartmouth College, Hanover, NH, United States b Sections of Hematology, Oncology and Neurology, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States c Dartmouth Medical School, Hanover, NH, United States d Section of Neurosurgery, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States e Department of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States f Neurosciences Unit, Institute of Child Health, University College London, Great Ormond Street Hospital for Children NHS Trust, London, UK A R T I C L E I N F O A B S T R A C T Article history: Purpose: Seizures frequently impact the quality of life of patients with low grade tumors. Management is Received 12 January 2012 often based on best clinical judgment. We examined factors that correlate with seizure outcome to Received in revised form 24 May 2012 optimize seizure management. Accepted 24 May 2012 Methods: Patients with supratentorial low-grade tumors evaluated at a single institution were retrospectively reviewed. Using multiple regression analysis the patient characteristics and treatments Keywords: were correlated with seizure outcome using Engel’s classification.
    [Show full text]
  • Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult With
    Khalayleh et al. Int Arch Endocrinol Clin Res 2017, 3:008 Volume 3 | Issue 1 International Archives of Endocrinology Clinical Research Case Report : Open Access Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult with Neurofibromatosis Type 1 Harbi Khalayleh1, Hilla Knobler2, Vitaly Medvedovsky2, Edit Feldberg3, Judith Diment3, Lena Pinkas4, Guennadi Kouniavsky1 and Taiba Zornitzki2* 1Department of Surgery, Hebrew University Medical School of Jerusalem, Israel 2Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Israel 3Pathology Institute, Kaplan Medical Center, Israel 4Nuclear Medicine Institute, Kaplan Medical Center, Israel *Corresponding author: Taiba Zornitzki, MD, Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Bilu 1, 76100 Rehovot, Israel, Tel: +972-894- 41315, Fax: +972-8 944-1912, E-mail: [email protected] Context 2. This is the first reported case of an adrenal neuroblastoma occurring in an adult patient with NF1 presenting as a large Neurofibromatosis type 1 (NF1) is a genetic disorder asso- adrenal mass with increased catecholamine levels mimicking ciated with an increased risk of malignant disorders. Adrenal a pheochromocytoma. neuroblastoma is considered an extremely rare tumor in adults and was not previously described in association with NF1. 3. This case demonstrates the clinical overlap between pheo- Case description: A 42-year-old normotensive woman with chromocytoma and neuroblastoma. typical signs of NF1 underwent evaluation for abdominal pain, Keywords and a large 14 × 10 × 16 cm left adrenal mass displacing the Adrenal neuroblastoma, Neurofibromatosis type 1, Pheo- spleen, pancreas and colon was found. An initial diagnosis of chromocytoma, Neural crest-derived tumors pheochromocytoma was done based on the known strong association between pheochromocytoma, NF1 and increased catecholamine levels.
    [Show full text]
  • A Rare Disease in Pediatric Patients
    Cartas ao Editor Jornal de Pediatria - Vol. 85, Nº 3, 2009 277 Resposta do autor Gliomatose leptomeníngea primária difusa: uma doença rara em pacientes pediátricos Prezado Editor, Recebemos com prazer os comentários acima. Os autores esclarecem que, em momento algum, focaram suas preo- Prezado Editor, cupações em critérios para definir síndrome metabólica, até mesmo porque se ela existe1, não existem critérios de consenso O recente relato de caso de Val Filho & Avelar1 sobre um para o diagnóstico em adultos2,3 tampouco em adolescentes. raro tumor cerebral pediátrico é interessante e merece grande Preocupamo-nos sim, em mostrar a presença de fatores de consideração no contexto da literatura publicada sobre esse risco em uma amostra selecionada ao acaso, que eles existem assunto, já que representa um evento muito incomum. Em em proporções tais que podem até ser agrupados, e, por um nome da precisão científica, devemos, portanto, fazer uma dos muitos critérios sugeridos na literatura, com valores de importante correção no que se refere ao diagnóstico. referências pediátricos, dar origem ao que se denomina sín- Os autores fizeram uma revisão breve e adequada sobre a drome metabólica. Não nos propusemos, portanto, a estudar gliomatose cerebral; uma doença rara, classificada pela edição associações entre fatores de risco. de 2007 da Organização Mundial da Saúde (OMS)2 como uma Os autores acreditam que discutir critérios para o que não lesão de grau III com prognóstico reservado. A gliomatose 2,3 existe consenso é desfocar a atenção da gravidade
    [Show full text]
  • Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations
    Published OnlineFirst July 13, 2018; DOI: 10.1158/1541-7786.MCR-17-0507 Genomics Molecular Cancer Research Desmoplastic Infantile Ganglioglioma/ Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations Anthony C. Wang1, David T.W. Jones2, Isaac Joshua Abecassis3, Bonnie L. Cole4, Sarah E.S. Leary5, Christina M. Lockwood6, Lukas Chavez2, David Capper7, Andrey Korshunov7, Aria Fallah1, Shelly Wang8, Chibawanye Ene3, James M. Olson5, J. Russell Geyer5, Eric C. Holland3, Amy Lee3, Richard G. Ellenbogen3, and Jeffrey G. Ojemann3 Abstract Desmoplastic infantile ganglioglioma (DIG) and desmo- transformation were found, and sequencing of the recurrence plastic infantile astrocytoma (DIA) are extremely rare tumors demonstrated a new TP53 mutation in one case, new ATRX that typically arise in infancy; however, these entities have not deletion in one case, and in the third case, the original tumor been well characterized in terms of genetic alterations or harbored an EML4–ALK fusion, also present at recurrence. clinical outcomes. Here, through a multi-institutional collab- DIG/DIA are distinct pathologic entities that frequently harbor V600 oration, the largest cohort of DIG/DIA to date is examined BRAF mutations. Complete surgical resection is the ideal using advanced laboratory and data processing techniques. treatment, and overall prognosis is excellent. While, the small Targeted DNA exome sequencing and DNA methylation sample size and incomplete surgical records limit a definitive profiling were performed on tumor specimens obtained from conclusion about the risk of tumor recurrence, the risk appears different patients (n ¼ 8) diagnosed histologically as DIG/ quite low. In rare cases with wild-type BRAF, malignant DIGA. Two of these cases clustered with other tumor entities, progression can be observed, frequently with the acquisition and were excluded from analysis.
    [Show full text]
  • Central Neurocytoma SNP Array Analyses, Subtel FISH, and Review
    Pathology - Research and Practice 215 (2019) 152397 Contents lists available at ScienceDirect Pathology - Research and Practice journal homepage: www.elsevier.com/locate/prp Case report Central neurocytoma: SNP array analyses, subtel FISH, and review of the T literature Caroline Sandera,1, Marco Wallenborna,b,1, Vivian Pascal Brandtb, Peter Ahnertc, Vera Reuscheld, ⁎ Christan Eisenlöffele, Wolfgang Kruppa, Jürgen Meixensbergera, Heidrun Hollandb, a Dept. of Neurosurgery, University of Leipzig, Liebigstraße 26, 04103 Leipzig, Germany b Saxonian Incubator for Clinical Translation, University of Leipzig, Philipp-Rosenthal Str. 55, 04103 Leipzig, Germany c Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstraße 16-18, 04107 Leipzig, Germany d Dept. of Neuroradiology, University of Leipzig, Liebigstraße 22a, 04103 Leipzig, Germany e Dept. of Neuropathology, University of Leipzig, Liebigstraße 26, 04103 Leipzig, Germany ARTICLE INFO ABSTRACT Keywords: The central neurocytoma (CN) is a rare brain tumor with a frequency of 0.1-0.5% of all brain tumors. According Central neurocytoma to the World Health Organization classification, it is a benign grade II tumor with good prognosis. However, Cytogenetics some CN occur as histologically “atypical” variant, combined with increasing proliferation and poor clinical SNP array outcome. Detailed genetic knowledge could be helpful to characterize a potential atypical behavior in CN. Only FISH few publications on genetics of CN exist in the literature. Therefore, we performed cytogenetic analysis of an intraventricular neurocytoma WHO grade II in a 39-year-old male patient by use of genome-wide high-density single nucleotide polymorphism array (SNP array) and subtelomere FISH. Applying these techniques, we could detect known chromosomal aberrations and identified six not previously described chromosomal aberrations, gains of 1p36.33-p36.31, 2q37.1-q37.3, 6q27, 12p13.33-p13.31, 20q13.31-q13.33, and loss of 19p13.3-p12.
    [Show full text]